Company news

Anavex Life Sciences Corp. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Anavex Life Sciences Reports Fiscal 2023 Year End Financial Results and Provides Business Update

November 26, 2023

Anavex Life Sciences to Announce Fiscal 2023 Year End Financial Results on Monday, November 27, 2023

November 23, 2023

Anavex Life Sciences Announces Grant of U.S. Patent Covering Blarcamesine (ANAVEX®2-73) for Treatment of Insomnia or Anxiety

November 21, 2023

Anavex Initiates Regulatory Submission of Oral Blarcamesine for Alzheimer’s Disease to European Medicines Agency (EMA)

November 19, 2023

Anavex Life Sciences Appoints Senior VP of Regulatory Affairs

November 5, 2023

Anavex Life Sciences Reports New Publication in Scientific Journal Demonstrating the Potential of ANAVEX®3-71 to Prevent Cognitive Decline in Alzheimer’s Disease

October 24, 2023

Anavex’s Phase 2b/3 Trial of Blarcamesine (ANAVEX®2-73) in Patients with Alzheimer’s Disease Shows Robust Clinical Efficacy and Slows Neurodegeneration

September 13, 2023

Anavex Announces Appointment of Dr. Marwan N Sabbagh, MD as Chairman of the Scientific Advisory Board

September 11, 2023

Anavex Life Sciences Reports Fiscal 2023 Third Quarter Financial Results

August 7, 2023

Anavex Life Sciences Reports Publication of ANAVEX®3-71 in Clinical Journal Confirming ANAVEX®3-71 Clinical Cardiovascular Safety

August 6, 2023

Anavex Life Sciences to Present at the BTIG Virtual Biotechnology Conference 2023

August 1, 2023

Anavex Life Sciences to Announce Fiscal 2023 Third Quarter Financial Results on Tuesday August 8, 2023

July 31, 2023

Long-term Clinical Study Demonstrates Disease Modifying Effects of ANAVEX®2-73 (blarcamesine) for Rett Syndrome

June 27, 2023

Anavex Life Sciences and Partex Group Announce Strategic Partnership to Leverage AI for Drug Development and Healthcare Sales Marketing Building a Patient-Centric Digital Ecosystem

June 26, 2023

Anavex Life Sciences to Present at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference

June 19, 2023

ANAVEX®2-73 (blarcamesine) Receives Compassionate Use Authorization for Pediatric Patients with Rett Syndrome

June 14, 2023

Anavex Life Sciences Reports Publication in Medical Journal Signifying Continued Commitment for Improvement of the Rett Syndrome Caregiver Outcome Measure RSBQ

June 11, 2023

Anavex Life Sciences Announces Completion of ANAVEX(®)2-73 (blarcamesine) EXCELLENCE Phase 2/3 Rett Syndrome Clinical Trial

June 5, 2023

ANAVEX Announces Issuance of New U.S. Intellectual Property Compositions Patent for ANAVEX®2-73 (blarcamesine)

May 31, 2023

Anavex Life Sciences Reports Fiscal 2023 Second Quarter Financial Results

May 8, 2023

Anavex Life Sciences to Announce Fiscal 2023 Second Quarter Financial Results on Tuesday, May 9, 2023

May 1, 2023

Anavex Life Sciences Announces Issuance of New U.S. Patent Expanding ANAVEX®2-73 (blarcamesine) Intellectual Property Portfolio for the Treatment of Hypertension

April 30, 2023

Anavex Life Sciences to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ

April 24, 2023

Anavex Life Sciences to Present at the 22nd Annual Needham Virtual Healthcare Conference 2023

April 9, 2023

ANAVEX®2-73 (Blarcamesine) Shows Clinical Benefit in Long-Term 48-Week Phase 2 Extension Study in Patients with Parkinson’s Disease Dementia

March 29, 2023

Anavex Life Sciences Appoints Former FDA Lead Neurology Statistician as Vice President Head of Biostatistics

March 8, 2023

Anavex Life Sciences Reports Fiscal 2023 First Quarter Financial Results

February 6, 2023

Anavex Life Sciences Announces Exceeding of Enrollment Target for the ANAVEX®2-73 (blarcamesine) EXCELLENCE Phase 2/3 Rett Syndrome Clinical Trial

February 1, 2023

Anavex Life Sciences to Announce Fiscal 2023 First Quarter Financial Results on Tuesday February 7, 2023

January 30, 2023

Anavex Strengthens Scientific Advisory Board with Investigator from Phase 2b/3 Alzheimer’s Trial

December 13, 2022

Anavex Life Sciences to Present at the 41st Annual J.P. Morgan Healthcare Conference

December 11, 2022

Anavex Life Sciences to Announce Management Webcast and Conference Call on Monday December 5, 2022

December 1, 2022

ANAVEX®2–73 (Blarcamesine) Phase 2B/3 Study Met Primary and Key Secondary Endpoints, Showing Statistically Significant Reduction of Clinical Decline in Global Clinical Study of Patients With Early Alzheimer’s Disease

November 30, 2022

Anavex Life Sciences Reports Fiscal 2022 Year End Financial Results and Provides Business Update

November 27, 2022

Anavex Life Sciences to Announce Fiscal 2022 Year End Financial Results on Monday November 28, 2022

November 22, 2022

Anavex Life Sciences to Present at the Guggenheim 4th Annual Immunology and Neurology Conference 2022

November 7, 2022

Anavex Announces U.S. FDA Orphan Drug Designation to ANAVEX®2-73 (blarcamesine) for the Treatment of Fragile X Syndrome

November 6, 2022

Anavex Life Sciences Announces Late-Breaking Presentation of Phase 2b/3 Data of Oral ANAVEX®2-73 (blarcamesine) for Early Alzheimer’s Disease at the Upcoming Clinical Trials on Alzheimer’s Disease (CTAD) Congress 2022

October 16, 2022

Anavex Life Sciences Announces Issuance of U.S. Patent Covering ANAVEX®2-73 (blarcamesine) for Neurodevelopmental Disorders Therapy

September 20, 2022

Anavex Life Sciences Reports New Publication in Medical Journal Highlighting the Relevance of SIGMAR1 Activation to Compensate for Early Alzheimer's Disease

August 22, 2022

Anavex Life Sciences Provides Business Update and Reports Fiscal 2022 Third Quarter Financial Results

August 8, 2022

Anavex Life Sciences to Announce Fiscal 2022 Third Quarter Financial Results on Tuesday August 9, 2022

August 2, 2022

Anavex Announces Long-lasting Effect of ANAVEX®3-71 Preventing Cognitive Decline in a Transgenic Rat Model of Alzheimer’s Disease at AAIC 2022

August 1, 2022

Anavex Announces First Entire Clinical Alzheimer’s Gene Pathway Data of ANAVEX®2-73 at AAIC 2022

July 30, 2022

Anavex Life Sciences Announces Its Very First Scientific Educational Video News Release

June 20, 2022

Anavex’s Publication Supports Clinical Biomarker for ANAVEX®2-73 in Fragile X Syndrome

June 7, 2022

Anavex Life Sciences to Present at the H. C. Wainwright Global Investment Conference 2022

May 18, 2022

Anavex Life Sciences Provides Business Update and Reports Fiscal 2022 Second Quarter Financial Results

May 9, 2022

Anavex Life Sciences to Announce Fiscal 2022 Second Quarter Financial Results on Tuesday May 10, 2022

May 2, 2022

Anavex Life Sciences Announces Presentations at the IRSF Rett Syndrome Scientific Meeting

April 26, 2022

← Newer news releases · Older news releases →

Calls

The 5 newest of 17 calls. Every call is listed under its year.

Decks

The 5 newest of 20 decks. Every deck is listed under its year.